Paediatric Medicines

2.5.5 Drugs affecting renin-angiotensin system


  • Tablets 2.5mg, 5mg, 10mg, 20mg

2.10 Fibrinolytic-drugs

Alteplase Actilyse Cathflo

  • 1 vial with powder contains:2 mg alteplase (corresponding to 1,160,000 IU)
  • Paediatric central venous catheter management

4.1.1 Hypnotics


  • Melatonin m/r 2mg tablets are approved for use only to aid sleep cycle synchronisation in children with sensory impairment, autistic spectrum disorder, in other neurodisability / neuropsychiatric / neurodevelopmental disorders including ADHD when behavioural measures have been insufficient and also to induce sleep in children undergoing sleep EEG.
  • Melatonin m/r 2mg tablets are licensed for use in adults over 55, use in children is an ‘off label' use. The MHRA state that, where available a licensed preparation should be used where possible (ie. 2mg tablets which are licensed)

4.4 Central nervous system stimulants

Methylphenidate CD

Lisdexamfetamine CD 

Dexamfetamine Sulphate CD


4.8.1 Control of epilepsy


  • Tablets 250mg, 500mg, 750mg, 1g (Category 3 MHRA)
  • Oral solutionSF 100mg/ml
  • Granules in sachets, 250mg, 500mg and 1000mg Desitrend (second line use only)
  • Concentrate for I/V infusion 100mg/ml 5ml vial

    4.8.2 Status epilepticus

    Midazolam Maleate Oromucosal (Epistatus) CD

    Other Useful Information

    Sodium valproate

    • Crushable tablet 100mg
    • E/C tablets 200mg, 500mg
    • m/r tablet 200mg, 300mg, 500mg (Category 2 MHRA)
    • m/r capsules 150mg, 300mg
    • LiquidSF 200mg/5ml
    • Intravenous injection 400mg

    MHRA Drug Safety Update 24th April 2018 

    Antibiotics Guidance for Primary Care

    5.1.7 Some other antibacterials

    Colistimethate sodium (Promixin)

    • Powder for nebuliser solution 1million-unit
    • For use in paediatrics only following initiation by specialist.

    5.7 Lyme Disease

    • For up to date information relating diagnosing and managing Lyme Disease including treatment doses for children see NICE Guideline NG95  April 2018 

    6.1.6 Blood Glucose Monitoring

    Freestyle Libre

    • Approved for use according to BSW STP Policy March 2018
    • Initiation, patient contract, prescribing and 6 month review to be managed by Specialist Teams 
    • Freestyle Libre BSW STP Policy March 2018

    6.5.1  Growth Hormone


    6.2.2  Bisphosphonates

    Zoledronic Acid

    • IV Infusion 800 micrograms/ml 5ml (4mg) vial
    • Osteogenesis imperfecta and other low bone mass conditions as per the Bristol Childrens Hospital Guideline. Six monthly infusion.

    Drooling Guidelines

    Hyoscine hydrobromide

    • Scopoderm® 1.5mg patch 
    • Not licensed for this indication.
    • Only licensed from age 10 for travel sickness. Change patch every 72 hrs

    Trihexyphenidyl tablets 

    • 2mg tablets, 5mg tablets, Oral solution 5mg/5ml x 200ml 
    • Not licensed for this indication.“Not recommended” for children in the SPC. But is listed in the BNF for children.
    • 1mg bd titrated up to 2mg tds 

    Glycopyrronium Sialanar

    • 320 micrograms /ml oral solution
    • Sialanar® is licensed for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders (short term intermittent use)


    Oralvac Compact 

    • Oral mucosal solution (unlicensed named patient) Consultant Specialist only
    • Liquid dispenser bottles (initial pack for updosing then a maintenance pack)
    • One to three sublingual doses (pumps approx 0.07ml) per day for 8-12 months per year for 3 years.
    • For treatment of severe allergic rhinitis and  severe allergic conjuntivitis not responding to standard treatment

    Last updated by: Joy Craine on 24-04-2018 18:10